SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon’s arm gets nod for Posaconazole Delayed-Release tablets from USFDA

08 Feb 2022 Evaluate

Biocon’s subsidiary company -- Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the United States Food and Drug Administration (USFDA). This product is indicated for use in the prevention of certain fungal infections in patients with severely weakened immune systems and is available in 100mg strength. This approval further adds to Biocon’s portfolio of vertically integrated complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

382.60 1.85 (0.49%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×